Clinical trialNCT05683418RecruitingPhase 1Interventional

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

SponsorTotus MedicinesEnrollment241HR+/HER2-negative Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Zelanna Goldberg, MD
Totus Medicines
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Spain

Instituto de Investigacion Oncologica Vall Dhebron (vhio) - Epon
Barcelona, Spain
Guzmán Alonso Casal, M.D.
Recruiting
Next Oncology - Hospital Quironsalud Barcelona - Ppds
Barcelona, Spain
Fabricio Racca, M.D.
Recruiting
Start Barcelona Hm Nou Delfos
Barcelona, Spain
Tatiana Hernandez Guerrero, M.D., Ph.D.
Recruiting
Hospital Clinico San Carlos
Madrid, Spain
Jorge Bartolome Arcilla, M.D.
Recruiting
Start Madrid Hospital Universitario Fundacion Jimenez Diaz - Edos
Madrid, Spain
Bernard Doger, M.D, Ph.D.
Recruiting
Start Madrid Hospital Universitario Hm Sanchinarro - Ciocc
Madrid, Spain
Irene Moreno, M.D.
Recruiting
Clinica Universidad de Navarra
Pamplona, Spain
Jose Maria Lopez Picazo, M.D.
Recruiting
Next Oncology - Hospital Quironsalud Madrid - Ppds
Pozuelo de Alarcón, Spain
Valentina Boni, M.D.
Recruiting
Hospital Clinico Universitario de Valencia
Valencia, Spain
Valentina Gambardella, M.D., Ph.D.
Recruiting

United States

Northwestern Memorial Hospital
Chicago, Illinois, United States
William Gradishar, MD
Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Gerburg Wulf, MD
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Antonio Giordano, MD, PhD
Recruiting
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Liawaty Ho, MD
Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Mark Diamond, MD, PhD
Recruiting
Sarah Cannon Cancer Center
Nashville, Tennessee, United States
Erika Hamilton, MD
Recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Jordan Berlin, MDVandana Abramson, MD
Recruiting
Texas Oncology - Flower Mound
Flower Mound, Texas, United States
Vibha T Thomas, MD
Recruiting
Virginia Cancer Specialists
Fairfax, Virginia, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 Feb 2023
Primary completion: 31 Dec 2027
Completion: 31 Dec 2027
Last update posted: 22 Apr 2026
Registered enrollment: 241
Registry id: NCT05683418

Cross-registrations

EU-CTR / CTIS (EudraCT)2023-505346-26-01

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.